RxDoctor Payments Data

Eric Areiter, MD

Ophthalmology · Ontario, CANPI 1427496264

Payments from drug & device makers

$13,064in general payments, 2019–2025

Across 140 payments — averaging $93.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$8K
  • Rxsight Inc$2K
  • AbbVie$962
  • Sight Sciences, Inc.$446
  • Alcon$323
  • Biotissue Holdings Inc.$311
  • plus $645 from 10 others

What the payments were for

  • Consulting fees$8,00061%
  • Speaking & faculty fees$260%
  • Travel & lodging$1011%
  • Food & beverage$4,64036%
  • Other$2972%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,064 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$323,070
Medicare patients
316
Services billed
1,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium60$21,003
RestasisCyclosporine17$14,560
LumiganBimatoprost36$14,253
IlevroNepafenac30$10,926
Bromfenac Sodium53$9,777
Prednisolone Acetate211$9,181
Latanoprost490$6,587
Brimonidine Tartrate234$5,864
MoxifloxacinMoxifloxacin Hcl211$4,768
RocklatanNetarsudil Mesylat/Latanoprost11$3,687
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat209$3,649
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$2,143
Dorzolamide Hcl100$1,627
Timolol Maleate165$1,500
Difluprednate13$1,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$962$28,81353 claims
NovartisIlevro$68$10,92630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Ontario

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →